Cold Hands: Drugs That Cause or Treat It

Why Certain Medications Make Your Hands Cold

Drugs that narrow small arteries in the fingers directly reduce blood delivery to the skin, and the result is pale, cold digits. The mechanism varies by drug class, but the endpoint is the same: vasoconstriction of the digital and palmar arteries that supply warmth to the hands.

Beta-adrenergic blockers are the most widely recognized offenders. By blocking beta-2 receptors on vascular smooth muscle, non-selective agents like propranolol remove a key vasodilatory signal. A prospective study published in the British Medical Journal found that patients on non-selective beta-blockers reported cold extremities at rates 2 to 5 times higher than those on placebo 1. Cardioselective agents (metoprolol, bisoprolol, atenolol) carry a lower risk because they preferentially target beta-1 receptors in the heart, though the selectivity is dose-dependent and fades at higher doses 2.

Stimulant medications used for ADHD (amphetamine salts, methylphenidate, lisdexamfetamine) promote norepinephrine release, which activates alpha-1 receptors on peripheral arterioles. The FDA prescribing information for mixed amphetamine salts lists peripheral vasculopathy, including Raynaud phenomenon, as a known adverse reaction 3. Parents and clinicians sometimes notice cold or discolored fingertips in children on stimulant therapy before other side effects emerge.

Ergot alkaloids (ergotamine, dihydroergotamine) and certain triptans exert direct vasoconstrictive effects on peripheral and cranial arteries. Severe digital ischemia from ergotism, though rare with modern dosing, remains a documented risk 4. Chemotherapy agents, particularly cisplatin, bleomycin, and vinblastine, can also provoke Raynaud-like symptoms through endothelial damage. A retrospective cohort found that 37% of patients treated with bleomycin-containing regimens developed new-onset Raynaud phenomenon during or after treatment 5.

The Full List of Drug Classes Linked to Cold Hands

Knowing which drugs can trigger cold hands helps clinicians identify a reversible cause before adding new prescriptions. The list extends beyond beta-blockers.

Clonidine and other centrally acting alpha-2 agonists reduce sympathetic outflow globally but can paradoxically increase peripheral vasoconstriction in some patients. Cyclosporine causes endothelial dysfunction and has been associated with new-onset Raynaud phenomenon in transplant recipients 6. Interferons (interferon-alpha, interferon-beta) trigger vasospastic episodes through immune-mediated vascular injury, reported in patients receiving therapy for hepatitis C and multiple sclerosis 7.

Nicotine, though not a prescription drug, deserves mention because smoking and nicotine replacement products cause potent digital vasoconstriction. A laser Doppler flowmetry study demonstrated that a single cigarette reduces fingertip blood flow by approximately 42% within 5 minutes 8.

Other agents occasionally implicated include bromocriptine, methysergide, and vinblastine. Cocaine and methamphetamine produce severe peripheral vasoconstriction and can cause frank digital necrosis with chronic use. The clinical approach starts simple: review the medication list, identify temporal correlation between drug initiation and symptom onset, and trial a switch when the offending agent is non-essential.

Nifedipine: The First-Line Treatment

Calcium channel blockers sit at the top of every major guideline for pharmacologic treatment of Raynaud phenomenon, and nifedipine is the most studied option in this class. It relaxes vascular smooth muscle through L-type calcium channel blockade, widening the digital arteries that spasm during cold exposure.

A Cochrane systematic review of 29 randomized controlled trials confirmed that calcium channel blockers reduce the frequency of Raynaud attacks by approximately 33% and decrease attack severity, though the effect size is moderate 9. The typical starting dose is nifedipine extended-release 30 mg once daily, titrated to 60 mg or 90 mg based on response and tolerability. Side effects include headache, flushing, ankle edema, and dizziness. Amlodipine 5 to 10 mg daily is an alternative with a longer half-life and fewer reflex tachycardia episodes 10.

"Nifedipine remains our go-to agent because it has the deepest evidence base and most clinicians are comfortable titrating it," noted Dr. Fredrick Wigley, Professor of Medicine at Johns Hopkins and a leading authority on Raynaud disease, in a review published in the New England Journal of Medicine 11.

The 2022 American College of Rheumatology guideline for the management of Raynaud phenomenon conditionally recommends dihydropyridine calcium channel blockers as first-line pharmacotherapy for patients whose symptoms do not respond to non-pharmacologic measures alone 12.

PDE-5 Inhibitors and Other Second-Line Options

When nifedipine fails or produces intolerable side effects, several second-line agents offer meaningful benefit. PDE-5 inhibitors (sildenafil, tadalafil) increase nitric oxide signaling in vascular endothelium, promoting vasodilation.

A meta-analysis of 6 RCTs (N=244) published in Annals of the Rheumatic Diseases found that PDE-5 inhibitors reduced daily Raynaud attack frequency by 0.49 attacks per day and decreased attack duration and severity scores compared with placebo 13. Sildenafil is typically dosed at 20 mg three times daily for Raynaud, well below the erectile dysfunction dose. The ACR guideline conditionally recommends PDE-5 inhibitors for patients with an inadequate response to calcium channel blockers 12.

Topical nitroglycerin applied to the affected fingers delivers local vasodilation without significant systemic hypotension. A randomized trial of a 0.9% nitroglycerin gel formulation (MQX-503) showed that treated fingers had higher resting blood flow and reduced pain scores during cold challenge, although the overall attack frequency reduction did not reach statistical significance in all endpoints 14.

Losartan, an angiotensin II receptor blocker, showed promise in a small crossover trial where 50 mg daily reduced the severity and frequency of attacks in primary Raynaud disease compared to nifedipine 40 mg daily 15. The evidence base is limited, but losartan may be a useful option for patients already requiring an ARB for hypertension.

Fluoxetine 20 mg daily reduced attack frequency in a 6-week pilot RCT, possibly through serotonin-mediated vascular effects, though the study was small (N=27) 16.

Intravenous Prostanoids for Severe Cases

Patients with secondary Raynaud phenomenon (associated with scleroderma, lupus, or mixed connective tissue disease) who develop digital ulcers or critical ischemia may need intravenous prostacyclin analogues. These cases go beyond simple cold hands into tissue-threatening territory.

Iloprost, a synthetic prostacyclin analogue, is administered as an intravenous infusion over 3 to 5 consecutive days. A landmark RCT demonstrated that iloprost infusion healed existing digital ulcers in 35% of scleroderma patients compared to 13% on placebo and reduced the number of new ulcers over a 9-week follow-up 17. The ACR 2022 guideline conditionally recommends IV prostanoids for patients with systemic sclerosis-associated Raynaud who have not responded to oral therapies 12.

"For patients with scleroderma-related digital ischemia, iloprost infusions can be limb-saving. We consider them when oral vasodilators have been maximized and ulceration is progressing," stated the ACR guideline committee's summary statement on severe Raynaud management 12.

Bosentan, an endothelin receptor antagonist, received FDA approval for reducing new digital ulcers in systemic sclerosis based on the RAPIDS-2 trial (N=188), which showed a 30% reduction in new ulcer formation compared to placebo over 24 weeks 18. It does not heal existing ulcers but serves a preventive role.

When Cold Hands Signal Something Beyond the Drug List

Not every case of cold hands traces back to a medication bottle. Primary Raynaud phenomenon, the benign vasospastic type, affects approximately 3% to 5% of the general population according to epidemiologic data from the Framingham Offspring Study 19. It is far more common in women, with a female-to-male ratio of roughly 4:1. Most people with primary Raynaud need only behavioral modifications: warming gloves, avoiding sudden cold exposure, and stress reduction.

Secondary Raynaud phenomenon, linked to autoimmune connective tissue diseases, requires a different workup. Nailfold capillaroscopy (a simple in-office exam using a dermatoscope or ophthalmoscope) can distinguish primary from secondary disease by revealing dilated or dropout capillary loops. The presence of anti-centromere or anti-Scl-70 antibodies alongside abnormal nailfold capillaries strongly predicts progression to systemic sclerosis 20.

Hypothyroidism reduces cardiac output and shifts blood flow away from the periphery. Anemia lowers oxygen-carrying capacity, which the body compensates for by shunting blood to vital organs. Peripheral artery disease narrows larger arteries upstream. Each of these conditions can produce cold hands independently of any medication, and each needs its own treatment.

How to Approach a Medication Switch

If a beta-blocker is causing cold hands, the switch depends on why the beta-blocker was prescribed. For hypertension, a calcium channel blocker (amlodipine, nifedipine) treats the blood pressure and the cold hands simultaneously. For heart rate control in atrial fibrillation, a cardioselective agent like bisoprolol at the lowest effective dose may reduce peripheral symptoms while maintaining rate control 2.

For patients on stimulants who develop cold digits, dose reduction is the first step. If symptoms persist, periodic drug holidays (weekends, school breaks) can provide relief. The American Academy of Pediatrics recommends monitoring for peripheral vasculopathy during stimulant therapy and discontinuing the medication if signs of digital ischemia emerge 21.

The key principle is temporal correlation. Cold hands that appeared within 2 to 4 weeks of starting a new drug and resolve within days of stopping it provide strong circumstantial evidence for a drug cause. Formal rechallenge is rarely necessary and is not advisable if ischemia was present.

Non-Drug Interventions That Work Alongside Pharmacotherapy

Heated gloves and chemical hand warmers are inexpensive and effective first-line tools. Biofeedback-assisted temperature training, where patients learn to voluntarily increase finger temperature through relaxation techniques, showed modest benefit in a controlled trial, with treated patients reporting fewer attacks over 12 months 22.

Smoking cessation is mandatory. The vasoconstrictive effect of nicotine directly opposes every vasodilator on the prescription list. Patients using nifedipine for Raynaud while continuing to smoke are fighting against their own pharmacotherapy 8.

Regular aerobic exercise improves endothelial function and may reduce vasospastic episodes, though large-scale trial data specific to Raynaud patients are limited. Avoiding vasoconstricting OTC medications (pseudoephedrine, phenylephrine) during cold months reduces the trigger burden. Cold hands patients should carry a medication card listing their current drugs so that urgent-care or ER physicians avoid prescribing conflicting vasoconstrictors.